{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:18:51Z","timestamp":1789611531920,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Isavuconazole is effective against invasive aspergillosis (IA) and mucormycosis (IM) and may improve clinical outcomes compared to alternative antifungal treatments. However, real-world evidence regarding its clinical use and the health economic burden of inpatient treatment for IA and IM of patients with haematological malignancies remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, matched, multicentre cohort study was conducted in six German tertiary care centres. The study included adults with haematological or oncological diseases who were diagnosed with proven, probable, or possible IA or IM. We compared clinical and health economic outcomes under first-line treatment initiated with isavuconazole (case group) vs. liposomal amphotericin B (L-AmB) and\/or voriconazole (control group) between 2016 and 2021. A micro-costing approach was used to assess direct treatment costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 198 patients (99 per group), most with a probable or possible classification. Median length of hospital stay was 44 days (interquartile range [IQR] 27\u201374) in the isavuconazole group and 39 days (IQR 26\u201356) in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.285). All-cause mortality rates were 29% and 31% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.530), with fungal-related deaths occurring in 21% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) and 23% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.862), respectively. Mean antifungal drug acquisition and overall treatment costs were significantly higher in the isavuconazole group (\u20ac22,389 vs. \u20ac12,801,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003; \u20ac49,042 vs. \u20ac39,369,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030, respectively), while mean hospitalisation costs were comparable (\u20ac28,570 vs. \u20ac31,160,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.406).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our real-world analysis confirmed that first-line treatment initiated with isavuconazole resulted in clinical outcomes equivalent to those of L-AmB and\/or voriconazole in patients with IA or IM. However, treatment costs during the in-patient stay were higher with isavuconazole.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02674-x","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:53:13Z","timestamp":1761922393000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in Germany"],"prefix":"10.1007","volume":"54","author":[{"given":"Marie","family":"Engelhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian M.","family":"Wingen-Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Gr\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.G.T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Niklas","family":"Baermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina M.","family":"P\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"1","key":"2674_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","volume":"44","author":"B Kably","year":"2022","unstructured":"Kably B, et al. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166\u201397.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2674_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/14787210.2024.2327517","volume":"22","author":"C Moya-Alarc\u00f3n","year":"2024","unstructured":"Moya-Alarc\u00f3n C, et al. Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain. Expert Rev Anti Infect Ther. 2024;22(8):713\u201320.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"2674_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/myc.13567","volume":"66","author":"J Jeck","year":"2023","unstructured":"Jeck J, et al. Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre. Mycoses. 2023;66(5):405\u201311.","journal-title":"Mycoses"},{"key":"2674_CR4","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.mam.2023.101215","volume":"94","author":"C Lass-Fl\u00f6rl","year":"2023","unstructured":"Lass-Fl\u00f6rl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med. 2023;94:101215.","journal-title":"Mol Aspects Med"},{"issue":"5","key":"2674_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","volume":"41","author":"MM Roden","year":"2005","unstructured":"Roden MM, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634\u201353.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2674_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/ciy181","volume":"67","author":"MD Zilberberg","year":"2018","unstructured":"Zilberberg MD, et al. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009\u20132013. Clin Infect Dis. 2018;67(5):727\u201335.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2674_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","volume":"17","author":"A Skiada","year":"2011","unstructured":"Skiada A, et al. Zygomycosis in europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859\u201367.","journal-title":"Clin Microbiol Infect"},{"issue":"Supplement2","key":"2674_CR8","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","volume":"57","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(Supplement2):S168\u201378.","journal-title":"Med Mycol"},{"key":"2674_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2019.04.006","volume":"83","author":"SM Heimann","year":"2019","unstructured":"Heimann SM, et al. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: a retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. Int J Infect Dis. 2019;83:130\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2674_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0039-3401992","volume":"41","author":"G Reid","year":"2020","unstructured":"Reid G, et al. Mucormycosis. Semin Respir Crit Care Med. 2020;41(1):99\u2013114.","journal-title":"Mucormycosis Semin Respir Crit Care Med"},{"issue":"8","key":"2674_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/myc.12631","volume":"60","author":"D Seidel","year":"2017","unstructured":"Seidel D, et al. FungiScope(\u2122) -global emerging fungal infection registry. Mycoses. 2017;60(8):508\u201316.","journal-title":"Mycoses"},{"issue":"3","key":"2674_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jhin.2018.11.003","volume":"101","author":"SM Heimann","year":"2019","unstructured":"Heimann SM, et al. Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. J Hosp Infect. 2019;101(3):339\u201346.","journal-title":"J Hosp Infect"},{"issue":"1","key":"2674_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","volume":"34","author":"R Harrington","year":"2017","unstructured":"Harrington R, et al. Cost-effectiveness analysis of isavuconazole vs. Voriconazole as First-Line treatment for invasive aspergillosis. Adv Ther. 2017;34(1):207\u201320.","journal-title":"Adv Ther"},{"issue":"suppl1","key":"2674_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/mmy\/myx101","volume":"56","author":"A Skiada","year":"2018","unstructured":"Skiada A, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl1):93\u2013101.","journal-title":"Med Mycol"},{"issue":"9","key":"2674_CR15","doi-asserted-by":"publisher","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","volume":"66","author":"JS Lewis","year":"2022","unstructured":"Lewis JS 2, et al. New perspectives on antimicrobial agents: isavuconazole. Antimicrob Agents Chemother. 2022;66(9):e0017722.","journal-title":"Antimicrob Agents Chemother"},{"key":"2674_CR16","doi-asserted-by":"crossref","unstructured":"Seyedmousavi SR, Ilkit H, Tolooe M, Hedayati A, Verweij MT. P. Systemic Antifungal Agents: Current Status and Projected Future Developments, in Human Fungal Pathogen Identification. Methods in Molecular Biology, T. Lion, Editor. 2017. pp. 107\u2013139.","DOI":"10.1007\/978-1-4939-6515-1_5"},{"issue":"10020","key":"2674_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"7","key":"2674_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337.","journal-title":"Lancet Infect Dis"},{"key":"2674_CR19","doi-asserted-by":"crossref","unstructured":"Desai AV et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. 2017;61(12).","DOI":"10.1128\/AAC.01034-17"},{"issue":"1","key":"2674_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","volume":"19","author":"L Floros","year":"2019","unstructured":"Floros L, et al. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect Dis. 2019;19(1):134.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2674_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/myc.13189","volume":"64","author":"JR Azanza","year":"2021","unstructured":"Azanza JR, et al. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses. 2021;64(1):66\u201377.","journal-title":"Mycoses"},{"issue":"1","key":"2674_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13696998.2019.1638789","volume":"23","author":"L Floros","year":"2020","unstructured":"Floros L, et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. J Med Econ. 2020;23(1):86\u201397.","journal-title":"J Med Econ"},{"issue":"12","key":"2674_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"9596","key":"2674_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"1","key":"2674_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"4","key":"2674_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1524-4733.2007.00301.x","volume":"11","author":"JM von der Graf","year":"2008","unstructured":"von der Graf JM, et al. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health. 2008;11(4):539\u201344.","journal-title":"Value Health"},{"key":"2674_CR27","unstructured":"Drummond MF, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; 2015."},{"key":"2674_CR28","unstructured":"InEK - Institut f\u00fcr das Entgeltsystem im Krankenhaus. 2025 [cited 2025; Available from: https:\/\/www.g-drg.de\/"},{"key":"2674_CR29","unstructured":"Arzneimittelinformation f\u00fcr. Deutschland. 2025; Available from: https:\/\/www.rote-liste.de\/"},{"key":"2674_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2217\/fmb-2016-0231","volume":"12","author":"E Bagshaw","year":"2017","unstructured":"Bagshaw E, et al. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Future Microbiol. 2017;12:515\u201325.","journal-title":"Future Microbiol"},{"issue":"7","key":"2674_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","volume":"19","author":"D Horn","year":"2016","unstructured":"Horn D, et al. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728\u201334.","journal-title":"J Med Econ"},{"key":"2674_CR32","doi-asserted-by":"crossref","unstructured":"Batista MV et al. Comparing the real-world use of isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study. J Fungi (Basel). 2023;9(2).","DOI":"10.3390\/jof9020166"},{"key":"2674_CR33","doi-asserted-by":"crossref","unstructured":"Qin J et al. Real-World effectiveness and safety of isavuconazole versus amphotericin B for patients with invasive mucormycosis. Microorganisms, 2025. 13(1).","DOI":"10.3390\/microorganisms13010055"},{"key":"2674_CR34","doi-asserted-by":"crossref","unstructured":"Dagher H et al. Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant. J Fungi (Basel). 2022;8(1).","DOI":"10.3390\/jof8010074"},{"issue":"12","key":"2674_CR35","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s40121-024-01064-4","volume":"13","author":"D Neofytos","year":"2024","unstructured":"Neofytos D, et al. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015\u20132019). Infect Dis Ther. 2024;13(12):2527\u201343.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2674_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/myc.12910","volume":"62","author":"H Hassouna","year":"2019","unstructured":"Hassouna H, Athans V, Brizendine KD. Real-world use-isavuconazole at a large academic medical center. Mycoses. 2019;62(6):534\u201341.","journal-title":"Mycoses"},{"issue":"10","key":"2674_CR37","first-page":"1033","volume":"30","author":"M Kwon","year":"2024","unstructured":"Kwon M, et al. Real-world experience with isavuconazole in allogeneic stem cell transplantation in Spain. Transpl Cell Ther. 2024;30(10):1033.e1-1033.e8.","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2674_CR38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/jac\/dkae139","volume":"79","author":"M Erg\u00fcn","year":"2024","unstructured":"Erg\u00fcn M, et al. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. J Antimicrob Chemother. 2024;79(8):1801\u201310.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02674-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:44Z","timestamp":1770021584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2674"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02674-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A primary ethics vote was obtained at the Ethics Committee of the Department of Medicine at the University of Cologne on 2021-06-22 (local ethics ID approval 21\u20131369-retro), as the University Hospital Cologne was the leading study site. The participating study site received their local ethics vote at the respective ethics commission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: ME has received travel grants from Tillotts and Pfizer. SMWH has received research and travel grants from Astellas, MSD, and Tillotts; research grants from Basilea, Gilead, and 3\u00a0M; travel grants from Pfizer, and lecture honoraria from Astellas, MSD, and Tillotts. MJGTV has received research grants from MSD, Heel, Roche, Tillotts, and consulting fees from GILEAD, Tillotts, Pfizer, Bioaster, GSK, Ecraid, and meeting and travel support from Akademie f\u00fcr Infektionsmedizin, Astra Zeneca, bioMerieux, DGI, European Society of Neurogastroenterology, Falk Foundation, FomF GmbH, GILEAD, GSK, Helios Kliniken, Hessisches Landessozialgericht, Infektio Forum, Janssen Cilag GmbH, Klinikum Kassel, Landes\u00e4rztekammer Hessen, LMU Kliniken, MSD, Pfizer, Streamed up, St. Vincent Hospital, Tillotts. JK has received organisation and speaker fees from Landes\u00e4rztekammer Hessen. SE has received speaker honoraria from Gilead. KS received speaker honoraria and\/or travel grants by and\/or has been consultant to Abbvie, Alexa, Bristol Myers Squibb, Jazz Pharmaceuticals, Leo, Pfizer, Sanofi, Servier, Sobi, Stemline, Takeda, MSD, Gilead. BNB received speaker honoraria, travel grants and has consulted to Beigene, Gilead, Jazz Pharmaceuticals, Bristol Myers Squibb, Incyte, Janssen Cilag. JJV received research grants from MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zentrum f\u00fcr Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen, German Network University Medicine, German Cancer Consortium (DKTK), German Federal Ministry of Health (BMG), European Union, speaker fees from MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg\/ Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), \u00c4rztekammer Nordrhein, \u00c4rztekammer Hessen, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universit\u00e4tsmedizin, Janssen, NordForsk, Biontech, APOGEPHA, German Cancer Consortium (DKTK), University Hospital Oldenburg, and meeting and travel support from German Centre for Infection Research (DZIF), University Manchester, German Society for Infectious Diseases (DGI), University Hospital Aachen, German Society for Internal Medicine (DGIM), Netzwerk Universit\u00e4tsmedizin, German Cancer Consortium (DKTK). SMP received travel grants and lecture honoraria from Tillotts. BG and ES have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}